Clinical trials: Head Neck Cancer
Head and Neck Cancer, Squamous Cell Carcinoma
Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy
The purpose of this study is to investigate the safety of zalutumumab in combination with radiotherapy as the treatment of patients with head and neck cancer who are not eligible for platinum based chemotherapy.
- Trial name
- NCT00707655
- Testing
- Zalutumumab
- Where
- 8 sites in Belgium, France and 1 more
- Volunteers
- 8 people
- Sponsor
- Genmab
Esophageal Neoplasms
A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer
This is a study of an investigational agent, pemetrexed, in combination with a standard chemotherapy drug, carboplatin, for treatment of patients with metastatic esophageal cancer.
- Trial name
- NCT00383266
- Testing
- Pemetrexed, Carboplatin
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Washington University School of Medicine
Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer
Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers
The purpose of this study was to assess the safety, tolerability, and efficacy when combining MK-3475 and INCB024360 in participants with certain cancers. This study was conducted in 2 phases, Phase 1 and Phase 2.
- Conditions
- Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT02178722
- Testing
- MK-3475, INCB024360
- Where
- 24 sites in United States
- Volunteers
- 444 people
- Sponsor
- Incyte Corporation
Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma
Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors
To determine whether special tumor fighting cells that is taken from participants' tumors and grown in the laboratory and then given back to the participant will fight the participant's cancer when their immune system is…
- Conditions
- Metastatic Melanoma, Locally Advanced Refractory/Recurrent Melanoma, Metastatic Head and Neck Cancer, Locally Advanced Refractory/Recurrent Head and Neck Cancer
- Trial name
- NCT03991741
- Testing
- Autologous Tumor Infiltrating Lymphocytes, High-Dose Interleukin 2
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Gregory Daniels
Head and Neck Cancer
Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer
The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel…
- Trial name
- NCT00971867
- Testing
- Paclitaxel
- Where
- 9 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Bristol-Myers Squibb
Squamous Cell Carcinoma of the Head and Neck
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)
The purpose of this study is to find out whether Nivolumab will significantly improve overall survival as compared to therapy of investigator's choice in patients with recurrent or metastatic head and neck carcinoma.
- Trial name
- NCT02105636
- Testing
- Nivolumab, Cetuximab, Methotrexate
- Where
- 64 sites in United States, Argentina and 13 more
- Volunteers
- 361 people
- Sponsor
- Bristol-Myers Squibb
Esophageal Cancer
Sutent + Taxol for Advanced Esophageal Cancer
Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens.
- Trial name
- NCT00730353
- Testing
- Sunitinib malate, Paclitaxel
- Where
- 15 sites in United States
- Volunteers
- 28 people
- Sponsor
- Hoosier Cancer Research Network
Recurrent Head and Neck Squamous Cell Carcinoma
Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer
This phase II trial studies how well intensity-modulated radiotherapy and nivolumab work together in treating patients with head and neck squamous cell cancer that has come back.
- Trial name
- NCT03521570
- Testing
- IMRT, Nivolumab
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- Emory University
Depression, Fatigue
Programs To Support You During Chemotherapy
This randomized pilot trial studies how well two supportive programs work for improving fatigue and depressive symptoms in patients with GI undergoing chemotherapy.
- Conditions
- Depression, Fatigue, Stage IIA Colorectal Cancer, Stage IIB Colorectal Cancer
- Trial name
- PRO-YOU (NCT02489422)
- Testing
- Laboratory Biomarker Analysis, Questionnaire Administration, Daily Survey Administration
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer, Squamous Cell Cancer
Zalutumumab in Patients With Non-curable Head and Neck Cancer
The purpose of this study is to investigate if zalutumumab in combination with Best Supportive Care (BSC) is superior to BSC in non-curable patients with head and neck cancer
- Trial name
- NCT00382031
- Testing
- Zalutumumab, Control
- Where
- 82 sites in Belgium, Brazil and 10 more
- Volunteers
- 286 people
- Sponsor
- Genmab
Prostate Cancer, Head and Neck Cancers
A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
This is Pilot study that investigates the CBCT(Cone beam computed tomography) image quality improvement provided by the 2D antiscatter grid technology.
- Conditions
- Prostate Cancer, Head and Neck Cancers, Upper Abdomen Cancers
- Trial name
- NCT04565457
- Testing
- Research CBCT
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of Colorado, Denver
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
A Phase 1/2, open label, multi-center study to evaluate the safety, efficacy and tolerability of alomfilimab as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies…
- Conditions
- Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer
- Trial name
- NCT03829501
- Testing
- Alomfilimab, Atezolizumab
- Where
- 22 sites in United States, Hungary and 4 more
- Volunteers
- 222 people
- Sponsor
- Kymab Limited
Esophageal Neoplasms, Esophageal Diseases
Erlotinib and Avastin in Patients With Cancer of the Esophagus or Gastroesophageal Junction
Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction
- Trial name
- OSI3650 (NCT00442507)
- Testing
- Erlotinib, Avastin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Washington University School of Medicine
Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer
A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
This pilot study will determine changes over time in tumor volume/motion \& patient anatomy, as well as dose distributions to normal organs.
- Conditions
- Biopsy Proven Non Small Cell Lung Cancer, Head and Neck Cancer, Gastrointestinal Cancer, Colorectal Cancer
- Trial name
- NCT02130427
- Testing
- CT scan
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Advanced Solid Tumors, Metastatic Solid Tumors
A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors
This is a Phase 1, open label, multi center, dose escalation and expansion, safety, tolerability, PK, and pharmacodynamics study of PF 06939999 in previously treated patients with advanced or metastatic cancer.
- Trial name
- NCT03854227
- Testing
- PF-06939999 dose escalation, PF-06939999 monotherapy, PF-06939999 in combination with docetaxel
- Where
- 22 sites in United States
- Volunteers
- 54 people
- Sponsor
- Pfizer
Esophageal Cancer
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
RATIONALE: Drugs used in chemotherapy, such as paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00655876
- Testing
- cetuximab, cisplatin, paclitaxel
- Where
- 175 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Radiation Therapy Oncology Group
Hypopharyngeal Neoplasms, Laryngeal Neoplasms
Assessing the da Vinci® Robotic Surgical System for Surgery of the Upper Aerodigestive Tract
To assess the use of the da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) in transoral surgeries in patients with benign and malignant lesions of the oral cavity and laryngopharynx.
- Conditions
- Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Head and Neck Cancers
- Trial name
- NCT00721539
- Testing
- da Vinci Surgical Robot Platform, Transoral Robotic Surgery
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Stanford University
Hodgkin Disease, Non-Hodgkin Lymphoma
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
The subject has a type of cancer or lymph gland disease associated with a virus called Epstein Barr Virus (EBV), which has come back, is at risk of coming back, or has not gone away after standard treatments.
- Conditions
- Hodgkin Disease, Non-Hodgkin Lymphoma, Severe Chronic Active Epstein Barr Virus, T/NK-lymphoproliferative Disease
- Trial name
- MABEL (NCT02287311)
- Testing
- MABEL CTLs, Cyclophosphamide, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Baylor College of Medicine
Squamous Cell Carcinomas
The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
This trial aims to directly compare a reduced radiation dose to the standard of care in HPVOPC for non-inferiority, thus allowing for direct comparison of outcomes between the two groups.
- Trial name
- NCT01706939
- Testing
- Reduced Dose Radiation, Standard Dose Radiation, Carboplatin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Oropharynx Cancer
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
This study is designed for patients with a cancer of the oropharynx (tonsils or base of tongue) caused by the HPV virus. Traditional treatment involves surgery followed by six weeks of daily radiation therapy.
- Trial name
- NCT02908477
- Testing
- Adjuvant Radiation Therapy, Docetaxel, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 228 people
- Sponsor
- Mayo Clinic
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.